# Lenograstim

Source: https://onco.cc/drugs/lenograstim/  
OnCo record `lenograstim` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lenograstim is Europe's and Japan's glycosylated form of G-CSF, given after chemotherapy to shorten the period of dangerously low neutrophils and to mobilise stem cells for transplant; it does the same job as filgrastim.

## Summary

Lenograstim is granulocyte colony-stimulating factor made in Chinese hamster ovary cells, so it carries the sugar chain of the natural protein, unlike filgrastim made in E. coli. It has been approved in Europe and Japan since the early 1990s to reduce the duration of neutropenia after cytotoxic chemotherapy and bone marrow transplantation and to mobilise peripheral blood stem cells in patients and healthy donors. Trials comparing it with filgrastim show equivalent efficacy at comparable doses. It was never approved in the United States.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-09-08
- Also known as: rHuG-CSF (glycosylated)
- Tags: gap-fill; chembl-universe
- Brand: Granocyte
- Modality: Recombinant glycosylated G-CSF, injection
- Mechanism: Activates the G-CSF receptor on neutrophil precursors to drive their proliferation, maturation and release from the marrow.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Lenograstim
- Wikipedia: https://en.wikipedia.org/wiki/Lenograstim
- ChEMBL CHEMBL1201567: https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201567

## Connected records

- technologies: [Cytokines & engineered cytokines](https://onco.cc/technologies/cytokine-therapy/)
- targets: [G-CSF receptor (CSF3R)](https://onco.cc/targets/csf3r/)
- drugs: [Filgrastim (G-CSF)](https://onco.cc/drugs/filgrastim/), [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/)
- companies: [Chugai Pharmaceutical](https://onco.cc/companies/chugai/)
- trials: [Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer](https://onco.cc/trials/nct00431080/), [Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer](https://onco.cc/trials/nct01985724/), [Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer](https://onco.cc/trials/nct00615602/)

---
JSON: https://onco.cc/api/v1/entities/lenograstim.json